Status:

COMPLETED

Explore the Efficacy and Safety of edoxabaN in Patients After Heart Valve Repair or Bioprosthetic vaLve Replacement (ENAVLE Trial)

Lead Sponsor:

Yonsei University

Conditions:

MV(Mitral Valve) Repair

Eligibility:

All Genders

20-85 years

Phase:

PHASE3

Brief Summary

1. objectives: The primary aim of ENAVLE is to explore the efficacy of edoxaban in patients with post mitral valve repair or bioprosthetic valve implantation 2. Primary / Secondary Endpoint 1\) Effic...

Detailed Description

This study is an open labeled, parallel group, and randomization study. At 7 days after mitral valve repair, bioprosthetic MV or AV replacement surgery, warfarin or edoxaban will be started per oral r...

Eligibility Criteria

Inclusion

  • Patients aged 20-85 years with
  • MV repair or Bioprosthetic MV or AV replacement
  • Patients with written informed consent

Exclusion

  • Previous mechanical prosthetic heart valve replacement
  • Patients who underwent TAVI
  • Concomitant bioprosthetic valve replacement of mechanical tricuspid or pulmonary replacement at the time of the index valve replacement surgery
  • Clinically relevant paravalvular leaks
  • Previous history of endocarditis
  • Complex congenital heart abnormality
  • Acute coronary syndrome within one month
  • Uncontrolled hypertension
  • Previous history of hemorrhagic stroke
  • At high risk for bleeding
  • Active hepatitis or liver dysfunction (AST/ALT\> 3times of upper normal limits)
  • Creatinine clearance \< 30ml/min
  • Patients with a clear indication for long-term dual antiplatelet therapy
  • Malignancy or radiation therapy within one month
  • Treatment with selected drugs that my interact with edoxaban (specific P-gp inhibitors, ie. verapamil, quinidine; the short-term use of azithromycin, clarithromycin, erythromycin, oral itraconazole, oral ketoconazole)
  • At of pregnancy or breastfeeding
  • Known allergy to warfarin or edoxaban

Key Trial Info

Start Date :

December 1 2017

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 30 2019

Estimated Enrollment :

220 Patients enrolled

Trial Details

Trial ID

NCT03244319

Start Date

December 1 2017

End Date

September 30 2019

Last Update

January 2 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Division of Cardiology, Yonsei Cardiovascular Hospital, Yonsei University College of Medicine

Seoul, South Korea, 03722